Barts Cancer Institute
10.0/10 Overall Rating
100% Positive
2 Orders Completed
London, GB
BCI was created in 2003, and brought together some of the most eminent cancer research teams in London. We are one of the six Institutes within the Barts and The London School of Medicine and Dentistry, Queen Mary University of London.
Under the leadership of the Director, Professor Nick Lemoine, and supported by an Executive Board of senior investigators, we have created an academic environment fitting for an internationally recognised, comprehensive cancer centre.
Barts Cancer Institute has a long tradition of pioneering research and innovation. Many surgical procedures were first discovered here as well as the use of radiotherapy to treat cancer.
By investing in and undertaking world-class research, we aim to prevent cancer and develop better diagnostic techniques and treatments. This will ultimately increase patient survival and enhance the quality of life for those with long-term disease.
A wide range of research is currently underway and includes:
We are recognised as one of the leading Cancer Research Institutions in the UK and are a Cancer Research UK Centre of Excellence - one of only 17 in the country.
The MS facility can provide access to advanced MS, proteomics and metabolomics technologies.
Proteomics
A series of analytical techniques that enable:
The mass spectrometry (MS) laboratory is a Core Service at Barts Cancer Institute and is currently managed by the Centre for Haemato-Oncology. MS has a variety of applications in cell and molecular biology and cancer research, including the analysis of:
Pharmacokinetics and pharmacodynamics of drugs
Samples' protein composition
Protein structures
Post-translational modifications of proteins
Enzymatic activity
MS is also the preferred analytical method in metabolomics and proteomics.
The MS Laboratory supports BCI researchers through collaborations in a variety of high quality m
Our Philosophy:
"We had a very good experience with Dr. Pedro Cutillas and team at Barts Cancer Institute, they followed our tight timelines and provided very robust data, we recommend this group for phosphoproteomics studies."
Barts Cancer Institute has not received any endorsements.